TENX

SEC Filing Summary: Synthetic Blood International, Inc. (10-K)

Business Context and Reporting Period

Company: Synthetic Blood International, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: April 30, 2006
Business Overview: A development-stage biotechnology company focused on creating perfluorocarbon-based medical products. The primary focus is Oxycyte, a synthetic blood substitute currently in Phase II clinical trials. Secondary products, Fluorovent (lung treatment) and an implanted glucose biosensor, are on hold pending additional financing. The company has no commercial revenue and relies entirely on external financing.

Key Financial Metrics

Liquidity & Debt: The company holds negligible cash ($382) and has negative working capital. Current liabilities include approximately $176,000 in convertible debentures and $15,000 in notes payable. The company has no lines of credit.

Material Changes vs. Prior Period

• Increased Losses: Net loss increased by approximately $1.4 million (52%) compared to FY2005, driven primarily by a $1.66 million interest expense related to convertible debentures issued in July 2005.
• Cash Depletion: Cash reserves dropped from $588,763 to $382 due to operating cash burn of $2.15 million.
• Working Capital: Shifted from positive ($352,505) to negative ($269,965), indicating a liquidity crisis.
• Expense Composition: Research and Development expenses decreased slightly ($1.28M to $1.20M) as resources were concentrated on Oxycyte, while General and Administrative expenses decreased ($1.41M to $1.27M) despite a $59,000 loss on patent write-offs.

Outlook, Risks, and Management Commentary

Going Concern Warning: The independent auditors have issued an explanatory paragraph expressing "substantial doubt" about the company's ability to continue as a going concern. Management explicitly states they do not have the working capital to fund operations in fiscal year 2007 and require immediate financing to avoid ceasing operations.

Clinical Progress:

• Oxycyte: Phase II trials are ongoing (started Q4 2004), expected to continue through 2007. A trial for severe brain injury patients began in 2006.
• Other Products: Development of Fluorovent and the glucose biosensor is on hold until financing is secured.

Financing Activities:

• In July 2005, the company issued $1.85 million in convertible debentures (net proceeds ~$1.13 million).
• Subsequent to April 30, 2006, the company raised an additional $118,200 via unsecured notes and issued warrants.
• Management is actively seeking equity and debt financing but notes no assurance of availability.

Risks:

• Regulatory: No assurance of FDA approval for Oxycyte; failure to obtain approval would terminate the business.
• Market: No experience in marketing or selling medical products; competition from established therapies and other blood substitute developers.
• Financial: High dilution risk from converting debt to equity; potential obsolescence of paused technologies.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $118,200 raised post-filing to cover immediate administrative and clinical costs.
• Debt Conversion: Review the terms of the convertible debentures ($0.22 conversion price) and the potential dilution to existing shareholders if converted.
• Clinical Milestones: Monitor the status of Phase II trials for Oxycyte, specifically enrollment numbers and safety data, as these are critical for future funding.
• Going Concern Status: Assess the likelihood of securing the substantial additional capital required for Phase III trials and commercialization.
• Patent Portfolio: Confirm the status of the $249,000 patent write-off and the remaining value of the intellectual property.